Scientists selected five NSCLC patient-derived xenografts (PDXs) with genetic alterations from established PDXs and the corresponding molecular targeted therapy was administered orally for 21 consecutive days.
[Molecular Cancer therapeutics]
7992332
{7992332:AAAAAAAA}
apa
50
1
171165
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/